Therapeutic Drug Monitoring for Biologics in Inflammatory Bowel Disease

Originally held May 8, 2024

Presentation Recording Coming Soon


Free for all participants.


Over the past 10 years, the therapeutic arsenal for inflammatory bowel disease has grown exponentially, from TNF inhibitors such as infliximab, to anti-integrins (e.g., vedolizumab) and anti-interleukins (e.g., ustekinumab, risankizumab) amongst other drug classes. Given that the monoclonal antibody therapies are generally immunogenic, there are several laboratory assays to monitor patients in reactive or proactive stages of response assessment. 

This webinar will cover the laboratory tests available to monitor patients using monoclonal antibody therapies for treatment of inflammatory bowel disease. Focus will be shared between analytical approaches as well as literature and practice recommendations for tests results interpretation.


Maria Alice Willrich, Ph.D.

Associate Professor of Laboratory Medicine and Pathology
Department of Laboratory Medicine and Pathology

Mayo Clinic
Rochester, Minnesota

Michelle D. Becker, Pharm.D., R.Ph., BCACP

Assistant Professor of Pharmacy
Division of Gastroenterology and Hepatology 

Mayo Clinic
Rochester, Minnesota

Learning objectives

Upon completion of this activity, participants should be able to:

  • Describe the analytical methods employed for the measurement of monoclonal antibody therapies concentration and anti-drug antibodies.
  • Differentiate between reactive and proactive monitoring of monoclonal antibody therapies.
  • Develop plan for therapeutic drug monitoring based on patient- and drug-specific considerations.
  • Interpret therapeutic drug monitoring lab results to determine best next steps for a medical treatment plan.

Intended audience

This webinar is appropriate for any provider who sees patients with inflammatory bowel disease, gastroenterologists, primary care internal medicine, laboratory directors, lab supervisors, pathologists, pharmacists, and laboratory send-out coordinators/managers.


The following types of credit are offered for this event:


Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.® program. This program has been approved for a maximum of 1.0 P.A.C.E.® contact hour.

State of Florida

Mayo Clinic Laboratories is approved as a Continuing Education Accrediting Agency for the Clinical Laboratory Sciences for the State of Florida. Florida Board of Clinical Laboratory Personnel has designated this program for General credit. This program has been approved for 1.0 contact hour.

To obtain credit

1. Watch the video.

2. Complete the posttest and evaluation that launches immediately following the video.

3. Generate and print your certificate(s).

Level of instruction for this program is intermediate.

Faculty disclosure

Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.


Contact us:

MCL Education

This post was developed by our Education and Technical Publications Team.